Home›Trial›NCT06035120
NCT06035120NARECRUITING

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

Study Summary

This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months.

Conditions
Emphysema, PulmonaryEmphysema or COPD
Interventions / Drugs
AeriSeal System
View on ClinicalTrials.gov ↗
Sponsor
LUNG
Pulmonx Corporation
Pulmonary Devices
D38/100
Study Details
Enrollment200 participants
Primary Completion—
Lead SponsorPulmonx Corporation
Data Retrieved2026-04-11 04:20:19.561448+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 200 participants
Sponsor Catalyst Profile

Pulmonx Corporation (LUNG) is the sponsoring company for this trial. BiotechSign currently grades this company D (38/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

LUNG Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.